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Abstract: New direct acting antivirals (DAAs) such as daclatasvir (DCV; BMS-790052), which target
NS5A function with picomolar potency, are showing promise in clinical trials. The exact nature of
how these compounds have an inhibitory effect on HCV is unknown; however, major resistance
mutations appear in the N-terminal region of NS5A that include the amphipathic helix and domain
1. The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is
also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Geno-
type 1a HCV is less potently affected by these compounds and resistance mutations have a greater
effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A
homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this
domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Daclatasvir
(DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and
serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A
expansive network which could explain its operation on the membranous web. Additionally, sul-
fates bound in the crystal structure may provide evidence for the previously proposed RNA binding
groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation, by domain 1.
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Introduction
Hepatitis C Virus (HCV) is expected to be an
increasing global healthcare concern.1 HCV is a
major cause of chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma (HCC) and is estimated to
infect up to 3% of people worldwide.2 No protective
vaccine currently exists against HCV and the most
common combination therapy based on pegylated-
interferon a2 and ribavirin are effective in only a
fraction of patients and these are plagued by
adverse effects,3 even in combination with new
drugs such as telaprevir (Vertex Pharmaceuticals)
and boceprevir (Merck & Co.).4,5 The HCV species is
highly genetically diverse and classified into six
genotypes (1–6) with more than 90 different sub-
types. Genotypes 1a and 1b are the most common,
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accounting for about 60% of global infections.6 The
distribution of HCV genotypes varies globally and
this heterogeneity affects virus pathogenicity and
their responsiveness to therapies (WHO, 2003).
Hence, current efforts being pursued in the treat-
ment of HCV are focused on the development of
direct acting antivirals (DAAs).7 The HCV genome
encodes 10 proteins–consisting of the structural pro-
teins; core, E1 glycoprotein and E2; and the non-
structural viral proteins p7, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B.8 All of the HCV proteins
are essential for efficient HCV propagation and are
therefore all potential targets for antiviral com-
pounds. The recently approved NS3–4A protease
inhibitors, telaprevir and boceprevir, used in combi-
nation with the established interferon and ribavirin
therapy have created a new standard of care for
patients with genotype 1 infections.9 In addition,
DAAs showing high potency against the functionally
well-characterized NS5B polymerase are already
showing promise in phase III clinical trials,10 while
HCV proteins p7, NS4B, and NS5A are currently
under investigation as therapeutic targets.11 The
continued development of combination therapies
with more effective and tolerable DAAs that also
allow the elimination of interferon-based regimes
will be fundamental in the future successful treat-
ment of HCV infection.12
NS5A is a 447 amino acid phosphoprotein of 56/
58 kDa implicated in a variety of roles from the rep-
lication of HCV RNA, the modulation of the host cell
responses and the assembly of viral particles.13–15
Despite this critical and expansive role in the virus
life cycle, no specific mechanism is yet ascribed to
NS5A. Domain 1 of NS5A consists of a zinc-binding
motif16 and an N-terminal amphipathic helix which
is necessary and sufficient for association of NS5A
with the ER membrane17 and the structure is essen-
tial for HCV genome replication.18 Domains 2 and 3
appear to form an intrinsically unstructured region
of the protein with roles in RNA replication and the
assembly of hepatitis C virus particles.15,19,20
The pivotal role of NS5A in virus replication
makes it an ideal target for inhibition. Recent high-
throughput screens (HTS) for inhibitors of HCV rep-
licon propagation yielded leads that were optimized
into compounds with picomolar inhibitory potency
Fig. 1. To date, no exact binding data have been vali-
dated, although resistant mutant analysis has
revealed several mutations within domain 1 of the
NS5A gene that confer sensitivity to inhibitors21 and
mono- and bis-crosslinking of a photoaffinity probe
with the N-terminal region of NS5A22 has been dem-
onstrated. An example of such a compound is dacla-
tasvir (DCV, Bristol-Myers Squibb, Wallingford, CT),
which is the representative of a mechanistic class
that exhibits picomolar half maximal effective con-
centrations (EC50) towards HCV replicon cell cul-
tures23 with the twofold symmetry playing an
important role in its effectiveness, particularly with
respect to pan-genotype inhibition. More specifically,
1a genotypes show lower sensitivity (approximately
5- to 10-fold lower) than the 1b genotypes with sym-
metrical or pseudo-symmetrical compounds and
resistance mutations generated in genotype 1a repli-
cons result in a greater increase in resistance (shifts
in EC50 values approximately 2 magnitudes greater)
than those conferred from similar mutations in
genotype 1b.24 However, smaller, monomeric com-
pounds can exhibit potent activity towards genotype
1b replicons but a much reduced potency towards
genotype 1a, initially viewed as a hallmark of the
NS5A inhibitor class.25
Crystal structures of genotype 1b NS5A domain
1 (NS5A-D1) have revealed the formation of dimers
during crystallization. Although the formation of
multimers or protein-protein contacts are inevitable
consequences of protein crystallization,26 there is
some in vitro evidence of dimerization27 and the
phenomenal potency of this class of dimeric com-
pounds has led to speculation that they act on a
physiologically-relevant dimer present in NS5A-D1
crystal structures. While unproductive binding can
occur,22 productive binding, hypothetically, over-
stabilizes NS5A dimerization21 potentially in the
form of an immature HCV polyprotein dimer, or
higher order multimer, to slow the cleavage of the
NS4B-NS5A precursor.28 This hypothesis is sup-
ported by the bis-crosslinking of NS5A by BMS-351,
Figure 1. Chemical structure of the family of NS5A-targeting
molecules.
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an inhibitor of HCV replication that incorporates
photo-activated functionality22 and the dramatic
improvement in potency obtained with symmetrical
and pseudo-symmetrical inhibitors relative to half
molecules, particularly with genotype 1a.29,30 The
first crystal structure of a NS5A-D1 construct con-
sisting of residues 25 to 215 from genotype 1b sub-
type Con1, revealed it to consist of two subdomains
and to contain a novel fold with a stabilising disul-
phide bond. Additionally, the asymmetric unit com-
prised a dimer with an intermolecular interface of
approximately 830 A˚2, which forms a large groove
that could accommodate viral RNA;31 this dimer has
served as the basis for the working model of the
NS5A-D1. Crystallization of a NS5A-D1 construct
from the same genotype and subtype containing resi-
dues 33 to 202 resulted in higher resolution struc-
tures and showed that the NS5A-D1 formed an
alternative dimer with a 910 A˚2 dimeric interface.
Through combining the two dimers, it was hypothe-
sized how a NS5A superhelical array could form.32
The first crystal form does not seem to be readily
reproducible and soaks of the second crystal form
with compounds has yet to yield structures of
ligand-bound complexes (unpublished data).
Neither crystallographic nor spectroscopic evi-
dence for compounds such as DCV binding to NS5A-
D1 is currently available although binding of a
structurally related affinity probe to genotype 1b
NS5A has been demonstrated.23 To address this and
investigate the differences between the compound’s
effect on genotypes 1b and 1a, we decided to deter-
mine the structure of NS5A-D1 from genotype 1a.
Our crystals of domain 1 from genotype 1a NS5A
show a new crystal form, and allowed structural
determination via X-ray crystallography to a resolu-
tion of 3.5 A˚. Intriguingly, our structure shows two
new dimeric forms of this domain. NS5A-D1 dimers
allow the formation of new hypothetical multimer
assemblies, which form an expansive network that
could operate in the membranous web. Experimental
observation of RNA binding13,27,33 support a hypoth-
esis that sulfates from the crystallization buffer
bound in the crystal structure may mimic a RNA
backbone and highlight the location of a RNA bind-
ing groove. Alternatively, this region of NS5A may
bind phosphorylated sites of NS5A domain 2 and 3
to alter its overall conformation and regulate pro-
gression from RNA synthesis to viral assembly: this
may explain how DCV expresses two MOAs,41 affect-
ing both viral replication and assembly, and blocking
hyperphosphorylation of NS5A.
Results
Crystal structure of genotype 1a NS5A-D1
Our crystals of genotype 1a NS5A-D1 represent a
new crystal form. The crystal structure consists of
four monomers of the genotype 1a NS5A-D1
arranged into T-shaped asymmetric units (Fig. 2 and
Supporting Information Fig. S1), which are juxta-
posed to form large solvent channels; the crystals
have a Matthews coefficient of 4.73 A˚3/Dalton and a
solvent content of 73.97%.34 Similar surfaces of the
molecule are exposed to the solvent as in the most
recent 1b NS5A Domain 1 dimer crystal structure.32
The overall fold of each monomer in our model
superposes well with the NS5A domain structures
from genotype 1b31,32 with an average Ca RMSD of
0.57 A˚ between 1a and 1b monomers. The zinc-
binding motif has the same coordination as the
genotype 1b NS5A Domain 1 with an average dis-
tance of 2.24 A˚ between coordinating sulphurs and
the zinc atom. These bond lengths are slightly less
than the ideal distance (2.356 0.09 A˚) for structural
metal zinc-coordination sites and slightly more than
the ideal distance (2.086 0.13 A˚) for catalytic metal
zinc-coordination sites.35 The arrangement and prox-
imity of residues Cys 142 and Cys 190 in our model
and the presence of electron density in between the
residues suggests the formation of a disulphide
bridge, despite the presence of DTT in the crystalli-
zation buffer, with a distance between the sulfur
atoms of 2.0 A˚, 2.0 A˚, 2.0 A˚, and 2.5 A˚ in monomers
A, B, C, and D, respectively. It is not known whether
this disulphide bond is physiologically important or
essential for HCV replication.16
Amino acids present in the construct that could
not be fitted to any electron density include the dis-
ordered N- and C-termini of three to four amino
acids and 13 to 16 amino acids, respectively, depend-
ing on the monomer. Loops between b-strands B7
and B8, and b-strands B8 and B9 could not be fully
modeled in monomer A, in which modeling of resi-
due Glu 172, and residues Gly 178 and Leu 179,
respectively, had to be omitted.
Situated in between monomers A, C and D,
there was a large unmodeled region in the electron
density difference map appearing to be coordinated
by nitrogens e from residues Arg41 and Arg81 from
monomer A and by a nitrogen h from Arg78 from
monomer B. Owing to the presence of these
positively-charged side-chains and the high concen-
tration of sulfate ions in the crystallization solution,
it was modeled as SO4
22 (Supporting Information
Fig. S2A). Arg41 and Arg 78 are strictly conserved
as positive amino acids (>90% Arg or Lys at position
41 and >95% Arg or Lys at position 78), whereas
Arg81 shows no conservation (Arg, Ser, Ala, Met, or
Leu substitutions at position 81). Although the elec-
tron density matched that expected for a sulfate ion,
we cannot rule out that this site is occupied by
another anion. Another region of electron density
was identified adjacent to monomer A but was not
modeled as it was less well defined. Nevertheless, it
shows potential coordination by Arg 44 from chain C
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and the backbones of Gly 45 and Met 72 from chain
A and we tentatively propose that this region
includes an additional sulfate ion (Supporting Infor-
mation Fig. S2B).
Dimer interfaces
Two new dimeric forms of NS5A-D1 are observed
from the crystal packing shown in the asymmetric
unit. Monomers A and B of our structure are related
by a twofold axis (179.9) perpendicular to their
length. Dimer AB displays a similar interface to
that previously reported,32 but one of the monomer’s
orientation is reversed creating a head-to-tail confor-
mation [Fig. 3(A)], rather than head-to-head. Dimer
AB has a smaller buried solvent-accessible surface
area of 435.1 A˚2 than that calculated for the Love
et al.32 dimer (957.1 A˚2), due to the more detached
packing of the two molecules—the distance between
the centers of mass of the monomers in dimer AB is
23.1 A˚ compared to 21.4 A˚ in the Love et al. dimer
Figure 3. (A) Monomers A (orange) and B (green) make up dimer AB. (B) A secondary structure alignment of monomer A from
our genotype 1a crystal structure with monomer B from the Love et al. dimer (blue). Dimer AB shares a similar dimer contact
face to the Love et al. dimer except it is less closely packed and in a head to tail conformation.
Figure 2. Genotype 1b and 1a NS5A domain 1 crystal structure dimers in ribbon representation. The side chain of tyrosine 93,
a major resistant mutation, is displayed as spheres. Monomers are shown in orange and green, and coloured in pastel for geno-
type 1b dimers. (A) The first crystal structure dimer31 forms a potential RNA-binding pocket. (B) The second genotype 1b
dimer32 are juxtaposed in parallel to form an extensive interface. (C) Monomers A and B from the genotype 1a NS5A domain 1
crystal structure share the same interface as the Love et al. dimer shown in B albeit with the monomers arranged in an antipar-
allel fashion. Use this link to access the interactive version of this figure. (D) Monomers C and D form a N-terminal, head to
head dimer. Use this link to access the interactive version of this figure.
This figure also includes an iMolecules 3D interactive version that can be accessed via the link at the bottom of this figure’s caption.
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[Fig. 3(B)]. The contact surfaces are formed by resi-
dues 97–99, 112–115, 149, 160–161. Amino acid resi-
dues Pro 97, Cys 98, and Thr 99 show low
conservation and are in contact with the conserved
residue Phe 120 of the other dimer. Conserved
amino acid residues Arg 122, Val 123, Ala 125, and
the non-conserved Ser 124 form contacts with con-
served residues Arg 160 and Phe 161 (which is Tyr
or His in other genotypes). All of these 10 residues
are also included in the contact area of the Love
et al. dimer, whose contact area also includes an
additional 14 residues. Pairs of residues forming
notable interactions reported in the Love et al.
dimer, such as the salt bridge formed by conserved
residues Glu 148-Arg 112, the backbone hydrogen-
bond between conserved residues Ala 92 and Gly 96,
and an electrostatic interaction between residues
Arg 48 and Glu 116, are not close enough to form in
dimer AB.
Monomers C and D form a second dimer CD
that shows an approximately twofold (173.6) sym-
metry axis, composed of the monomers aligned in a
head to head conformation [Fig. 4(A)]. The mono-
mers form a buried solvent-accessible surface area of
315.0A˚2. The contact surfaces are formed by residues
74 to 78 and 83 to 84. Residues 74 to 78 from each
molecule appear to form an intermolecular anti-
parallel b-sheet through an extension of b-strand B3
from Val 75 to Arg 78 [Fig. 4(B)]. The formation of
this intermolecular b-sheet does not disrupt the b-
sheets within each molecule. All the residues
involved in the intermolecular b-sheet Ile 74 to Arg
78 are conserved. Residues 83 to 84 from each mole-
cule may stabilize the dimer through additional van
der Waals interactions. Met 83 shows conservation
as a hydrophobic residue (>99% residues are Met,
Thr, Val, or Ile) while Trp 84 is highly conserved
(>95% Trp). In forming the intermolecular b-sheet,
the refined structure shows intermolecular backbone
hydrogen bonds between pairs of residues Ile 74 O
with Arg 78 NH, and Gly 76 NH with Gly 76 O.
Copies of dimer CD are packed together in the crys-
tal with the same interface observed in dimer AB.
Simulation of the NS5a CD-dimer/DCV complex
The physical chemical properties and dimensions of
the cleft between the head-to-head CD-dimer match
well with that of the DCV molecule. Although crys-
tal soaking experiments with DCV failed, this is not
surprising as the amphipathic helix and its linker is
absent in our structure. The high frequency of
escape mutants occurring in this region suggests an
Figure 4. (A) Monomers C (orange) and D (green) make up dimer CD. (B) A secondary structure alignment of monomer A from
the Love et al. dimer (blue) with each monomer C and D shows an extension of b-strand B3 from Val 75 to Arg 78. (C) Hydro-
gen bonds are formed between residues Ile 74 O and Arg 78 NH, Gly 76 NH and Gly 76 O, forming a total of four hydrogen
bonds in the CD dimer.
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active role drug binding. We therefore performed
molecular dynamic simulations to add the experi-
mental NMR structure of the N-terminal helix to
our structure and model DCV into the interdimer
cleft. In the final modeled structure the central floor
region of the cleft is composed of hydrophobic resi-
dues Val75, Gly76, and Pro77 which lay under the
biphenyl core and between the caps of DCV while
the periphery of the putative binding site contains
more polar residues including His54, Arg56, Glu62,
His66, Arg73, and Thr79 which are proximal to the
cap regions of DCV (Fig. 5). The only hydrogen-
bonds between DCV and the NS5A CD-dimer
observed in the docked model are between the back-
bone NH’s of Glu62 and the two DCV valine carbon-
yls (Fig. 5). To further evaluate the putative binding
model, a 40 ns MD simulation was conducted. The
model drifted slightly from the starting structure
over the heating and equilibration phase and then
stabilized (Fig. 5). Each monomer and DCV
remained stable over the production phase; however,
the RMSD for the CD-dimer shows a slow oscillation
as the structure fluctuates about the long symmetry
axis (see movie, supplemental material). The mean
distance between DCV and the amino acids that line
the putative binding cleft within the CD-dimer are
shown in Supporting Information Table I. The two
hydrogen-bonds observed between DCV and the
dimer did not remain constant but periodically
formed and broke throughout the simulation.
Figure 5. DCV docked into the cleft between the CD dimer. The surface of the dimer is coloured by its electrostatic potential
(red is negative, gray is neutral, and blue is positive). The N-terminal residues are shown in ribbon (C-domain in green, D-
domain is orange). Key resistant positions are shown with van der Waals surface (carbon: gray, nitrogen: blue, oxygen: red, sul-
fur: yellow, polar hydrogen: white). DCV is shown in a ball and stick depiction (carbon: aquamarine). A) Top view of DCV
docked symmetrically through the cleft. B) Side view focuses on the cap of DCV docked into the cleft. Yellow dotted lines indi-
cate the hydrogen bond between the DCV valine carbonyl and the NS5A Glu62 backbone amide NH. Note: L31 packs against
the cap valine moiety of DCV. C) Communication network between DCV and Tyr93. The ribbon depiction of the CD monomer is
shown in green and orange, respectively. The van der Waals surface of the DCV (carbon: aquamarine) and the Glu62, Arg56,
and Tyr93 (carbon: gray) communication network. Use this link to access the interactive version of this figure.
This figure also includes an iMolecules 3D interactive version that can be accessed via the link at the bottom of this figure’s caption.
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The most frequently observed, clinically-
relevant NS5A genotype 1a (GT-1a) resistance muta-
tions have been identified at amino acids 28, 30, 31,
and 93 and the linked positions Q30R-E62D,
whereas for GT-1b, the major resistant changes
occurred at residues 31 and 93.36 The key resistance
mutation that is present in our structure is Tyr93.
Although this residue does not reside directly within
the putative binding site, it is connected to DCV via
a communication network in the MD simulation.
During the course of the simulation, DCV intermit-
tently hydrogen-bonds with Glu62 via the backbone
amide NH to the DCV valine carbonyl or the Glu62
side-chain and the DCV imidazole NH; Glu62, in
turn, periodically forms a salt bridge with Arg56
which packs against Tyr93 to complete the network.
This allosteric mechanism of resistance is supported
by the recent demonstration that resistant NS5A
does not necessarily eject an inhibitor and that bind-
ing of an inhibitor to NS5A alone is not sufficient for
inhibition.22 It is worth noting that mutations are
often to smaller or more flexible residues, which
may allow NS5A to recover its ability to articulate
in the presence of an inhibitor leading to a more
flexible dimer interface or allowing NS5A to popu-
late other dimer structures that are required for
function. Interestingly, the communication network
between Tyr93 and DCV also contains Glu62, a posi-
tion that has been associated with resistance. How-
ever, Glu62 resistance normally arises when linked
with the primary Q30R mutation.36
Discussion
It has been established that dimeric inhibitors,
either symmetrical or pseudo-symmetrical, are a key
factor in the antiviral activity in their compounds
such as DCV, which shows 50 and 9 pM EC50 values
against 1a and 1b HCV replicons, respectively. Key
resistance mutations are generated at Leu 31 and
Tyr93 in both genotypes and additionally at Met28
and Gln30 in genotype 1a.23 Similar resistance pro-
files are generated in response to treatment with
structurally related compounds including BMS-766
(Bristol-Myers Squibb), Ledipasvir/GS-5885 (Gilead
Sciences), GSK2336805 (GlaxoSmithKline), PPI-461
(Presidio, structure not disclosed) as well as
AZD7295 (AstraZeneca/Arrow Therapeutics) which
represents a distinct chemotype that only weakly
inhibits genotype 1a HCV (Fig. 1). The crystal struc-
ture the genotype 1a NS5A reveals that these crys-
tals have very high solvent content. Our new crystal
form is therefore likely to be amenable to soaks with
large compounds and would serve as an additional
tool in the development of novel NS5A-targeted
therapeutics.
The current working hypothesis is that such
compounds act on an NS5A dimer, based on the
dimeric nature of DCV analogs, the location of NS5A
resistance mutations, and mono- and bis-
crosslinking data, albeit with a lack of crystallo-
graphic or spectroscopic evidence. Publication of the
crystal structure for two genotype 1b dimers31,32 has
caused debate as to which dimer is biologically rele-
vant or whether several dimer forms are of impor-
tance. Our new results provide further candidates
for physiologically-relevant NS5A dimers. Due to the
dimensions of the compounds targeting NS5A, we
deem that the head to tail conformation of dimer AB
places the two N-termini too far apart, although this
does not rule out another physiological role for
dimer AB. The monomers of dimer CD have adjacent
N-termini and this dimer could represent a potential
target of the compound. Although dimer CD has a
relatively small buried solvent accessible surface
area of 315.0 A˚2, the inclusion of the N-terminal
amphipathic helix in vivo may further stabilize its
formation. It is conceivable that DCV may disrupt
the HCV life cycle by stabilizing the formation of a
weak dimer such as the dimer CD.
Through the use of molecular docking and
molecular dynamics we have shown that the binding
cleft between the head-to-head CD-dimer could
accommodate DCV in a fashion such that the key
resistance mutations lie in proximal to the inhibitor.
This demonstrates the CD-dimer could serve as a
potential binding site for DCV in addition to the pre-
vious models which show DCV could interact with
Table I. Crystal Data Collection and Refinement
Statistics
Crystal parameters
Space group P212121
Cell dimensions a5 100.25 A˚;
b5 101.53 A˚;
c5 148.70 A˚
Molecules per asymmetric unit 4
Data collection
Beamline DLS I24
Wavelength (A˚) 0.97780
Resolution range (A˚) 51.475–3.5 (3.67–3.5)
Unique observationsa 17168 (1226)
Rmerge
a 0.135 (0.388)
<I>/rIa 3.5 (1.9)
Completeness (%)a 86.0 (87.5)
Multiplicitya 3.4 (3.3)
Refinement
Rwork/Rfree(%) 22.49/26.64
No. protein residues in monomer 159
RMSD stereochemistry
Bond lengths (A˚) 0.0147 (monomer A)
Bond angles () 2.453 (monomer A)
RMSD of monomers
B to A (A˚) 0.412
C to A (A˚) 0.454
D to A (A˚) 0.622
PDB accession code 4CL1
a PDB, Protein Data Bank. Values reported in the format:
overall data (last resolution shell). RMSD (root-mean-
square deviation) stereochemistry is the deviation from
ideal values.
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genotype 1b dimers.22 Specifically, the two muta-
tions observed in our structure (Y93H and E62D)
are within two amino acid layers of DCV and estab-
lish a communication network through R56. How-
ever, based on the relative strength of the Y93H and
E62D resistance that is observed, we cannot rule out
that other binding modes are possible as DCV has
been shown to complement the symmetry of the
previous NS5A dimers close to primary clinical
resistance sites. Binding poses of BMS-411with the
face-to-face NS5A domain I dimer structure from
Tellinghuisen et al.31 and GSK2236805 with the
back-to-back Love et al. structure32 have been previ-
ously proposed.22,37,38 As with our dimer model
reported herein, the amino-terminal amphipathic a-
helix was modeled using the NMR structure by
Penin et al.39 All the models suggest a symmetric
binding mode along the dimer interface where inhib-
itors can interact with regions proximal to resistance
mutations at positions at 28, 30, 31, 54, and 93 and
genotype 1a/1b changes at positions 28, 30, 54, 56,
58, and 62. While the Love et al. dimer provides a
cleft for binding with good shape complimentarily to
the NS5A inhibitors, the chemical nature of the cleft
is reversed from that of the inhibitors. Specifically,
the hydrophobic biphenyl core of the inhibitor is
positioned over the two adjacent T95 amino acid res-
idues at the center of the dimer interface and the
polar imidazole moieties sit over the hydrophobic
aromatic ring of the Y93 side chains. A better match
is seen in the BMS model where the inhibitor core
lies over the two adjacent F37 residues at the dimer
interface and the imidazoles are positioned for
hydrogen bonding with Q62 from each monomer and
the N-terminus is placed adjacent to the inhibitor.
However, it should be noted that, unlike our dimer,
this crystal structure does not present a cleft for
inhibitor binding in the absence of the modeled in
N-terminal helix. While each model has its merits, it
is also conceivable that packing forces contribute to
the formation of dimeric species during crystalliza-
tion and these may not be physiologically signifi-
cant. Our preferred explanation is that NS5A binds
a variety of cellular targets and these dimers
explain some of the multiple interactions of NS5A.
Additional mutational and structural studies are
needed to elucidate the precise details of the NS5A/
inhibitor complexes.
The discovery of our new NS5A dimers suggests
that the formation of an extended multimeric net-
work of NS5A may occur through the utilization of
various dimer interfaces. The combination of the two
genotype 1b NS5A-D1 dimers allowed the formation
of a superhelical array that provides a model for the
oligomerization of NS5A and NS5A-D1 constructs
observed in vitro. However, the formation of this
higher order oligomer into a non-planar, superhelical
array precludes its association with a lipid bilayer.32
By combining the different conformations of the new
NS5A-D1 dimers present in our crystal structure,
one can envisage an array of NS5A molecules that
forms a more expansive network that could interact
with the membranous web (Supporting Information
Fig. S3). NMR experiments of NS5A constructs have
shown the protein can reversibly aggregate in a con-
centration dependent manner (data not shown), pos-
sibly into ordered oligomeric states. Such complexes
could imaginably have roles in the formation of the
membranous web, the replication complex, and/or
the assembly complex on lipid droplets.
As SO4
22 and the phosphate from an RNA back-
bone have similar conformations and charge, it could
potentially mimic the natural RNA ligand of NS5A.
Interestingly, while the sulfate bound within our
crystal structure performs a stabilizing role in crys-
tal formation, a structural alignment of monomer A,
which coordinates the SO4
22 via residues Arg 41
and Arg 81, with the Tellinghuisen et al. genotype
1b structure places the anion in their proposed
RNA-binding groove31 (Fig. 6). Alignments with
other NS5A domain 1 dimers do not place the SO4
22
Figure 6. Viral RNA approximately modeled into NS5A
domain 1 dimer. A structural alignment of monomer A and its
associated sulfates from our genotype 1a crystal structure
with each monomer in the Tellinghuisen et al. dimer places
the sulfates in the dimer’s RNA-binding groove. The sulfates
may be mimicking an RNA phosphate backbone allowing the
modeling of viral RNA into the dimer. Use this link to access
the interactive version of this figure.
This figure also includes an iMolecules 3D interactive version
that can be accessed via the link at the bottom of this figure’s
caption.
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in any recognizable RNA binding groove. Assuming
these to represent physiological RNA binding sites,
it is possible to accommodate the approximate posi-
tion of viral RNA (7rU) in the proposed RNA-
binding groove of the Tellinghuisen et al. structure31
suggesting this “arched” dimer may be relevant for
RNA binding by NS5A in the HCV life cycle (Fig. 6).
Another possible role for this binding site could
be to sequester the phosphorylated C-terminus of
NS5A. Phosphorylation of NS5A is thought to regu-
late its interaction with a variety of host and viral
binding partners, hence regulating HCV replication
and assembly. Therefore binding of a phosphorylated
residue within the C-terminal would alter NS5A
specificity for target host proteins and progression
through the viral life cycle. This could explain how
the targeting of NS5A inhibitors to NS5A-D1 could
affect phosphorylation in domains 2 and 3, and halt
the transition from viral RNA replication to virus
assembly.28 Recently, the hyperphosphorylation of
NS5A in domains 2 and 3 has been shown to be
dependent on the phosphorylation of at least one
residues in NS5A domain.40 This regulation of NS5A
domains 2 and 3 by domain 1 could explain findings
that have determined that DCV expresses dual
MOAs: interfering with the roles of NS5A in both
viral RNA synthesis and virion assembly,41 with the
latter being an offshoot of NS5A-D1 dimer destabili-
zation/stabilization.
Our current understand the mode of action for
NS5A inhibitors centers on the disruption of the for-
mation and function of the replication complex.22 It
is thought that the compound-interaction site on the
surface of NS5A is exposed only transiently during
the HCV life cycle, which explains why interactions
with NS5A have only been detected by treatment of
whole replicons with compounds and not in
vitro.22,23 The binding of inhibitors to NS5A perhaps
during replication complex formation, could result in
conformational changes to NS5A and the subsequent
formation of non-functional replication complexes.22
The isolation of a NS5A dimer via chemical cross-
linking of photoaffinity DCV analogs, provided the
first direct evidence of compounds interacting with
the N-terminal region of NS5A22 and emphasized
the importance of dimerization of NS5A in the HCV
life cycle and its inhibition. The structural distortion
of NS5A by the DCV analogs may result in inhibi-
tion of the replication complexes through concerted
communication through NS5A multimers.42 The
NS5A domain 1 allows a variety of multimerized
NS5A complexes to be built into an NS5A network.
We suggest that all of the observed NS5A dimers
could be physiologically relevant and involved in the
formation of this network. Within this proposed net-
work, at least one dimer mode would be the target
of these dimeric DCV-like inhibitors leading to net-
work disruption and malfunction of the replication
complexes. As NS5A has multiple roles and NS5A
inhibitors affect viral RNA synthesis and virion
assembly,41 we suggest this proposed NS5A network
also serves a purpose in viral assembly. The new
dimer modes observed in the genotype 1a NS5A
structure not only extends our knowledge of interac-
tional surfaces that could play a role in the action of
symmetrical NS5A inhibitors, but supports the
notion that NS5A dimers play a critical physiological
role in the viral life cycle.
Materials and Methods
Cloning and purification of 1a NS5A D1
Recombinant 1a (isolate H77) NS5A (residues 33–
202) with a N-terminal TEV protease cleavage site
(ENLYFQGSM) was expressed using the pET32
plasmid in BL21(DE3) Escherichia coli (Novagen) at
15C for 16 h. Cells were harvested and resuspended
in a wash buffer consisting of 100 mM Tris-HCl (pH
8.0), 300 mM NaCl, 10 mM imidazole, 10% glycerol,
in addition with the protease inhibitors aprotinin at
2 lg/mL, leupeptin at 10 lM, pepstatin at 1 lM and
phenylmethanesulfonylfluoride at 1 mM (Melford).
The cell lysate supernatant was loaded onto a 5 mL
HisTrap FF Crude (GE Healthcare) affinity column
and washed with 100 ml of the wash buffer and
eluted using the same buffer with 500 mM imidaz-
ole. The concentration of fractions containing the
fusion protein was determined using a NanoDrop
1000 (Thermo Scientific) and the fractions were
pooled and desalted into the wash buffer. One milli-
gram of TEV protease (produced in-house43) per 100
mg of fusion protein was added for overnight cleav-
age at 20C. After TEV protease cleavage, the His-
thioredoxin-tag and TEV protease were removed
from the cleaved sample by passing it through a sec-
ond 5 mL HisTrap FF Crude (GE Healthcare) and
collecting the flow-through and wash fractions,
which were pooled and concentrated before injection
onto a S75 column (GE Healthcare) equilibrated
with a crystallization buffer consisting of 20 mM
Tris HCl, 150 mM NaCl, 10% glycerol, pH 8.0, 5 mM
dithiothreitol (DTT).
Crystallization of 1a NS5A D1
Protein was concentrated to 8 mg/mL as determined
with a NanoDrop 1000 (Thermo Scientific). To
remove any precipitation, samples were subject to
centrifugation at 16,060 g for 2 min. Initial hits
were obtained from sparse matrix screens using sit-
ting drop plates with 100 nL reservoir added to 100
nL protein with a mosquito crystallization robot
(TTP LabTech) before sealing and incubation of the
plates at 4C. The largest crystals were grown using
microseeding with the crystals from the original con-
dition containing 0.1 M MES pH 6.5, 1.6 M MgSO4
which were crushed and used as a seeding stock for
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an optimization plate consisting of sitting drops of 2
mL of the protein sample with 2 mL reservoir. After
30 days incubation at 4C, crystals were visible and
grew to a full size of up to approximately 150 mm
after 60 days.
X-ray data collection and structure
determination
Crystal hits were fished out of the solution in 0.1 to
0.2 mm cryoloops (Hampton), before being immersed
briefly in a buffer consisting of 0.1M MES pH 6.5,
1.6 M MgSO4 and 30% glycerol, and then flash fro-
zen in liquid nitrogen. Native data sets were col-
lected using a PILATUS 6M detector at the micro
focus beamline I24 at Diamond Light Source. Diffrac-
tion data was processed with xia2 (Winter, 2009) and
phases were calculated with Phaser44 using the
genotype 1b NS5A domain 1 structure (PDB code:
1ZH1) as a search model. The process of refinement
using Phenix.refine with NCS restraints45 and model
building was iterated. The model was validated using
Molprobity and deposited within the PDB as 4CL1.46
Data collection and final refinement statistics are
given in Table I. Buried solvent accessible surface
area, rotation angles and distances between centers
of masses of the dimers were calculated with Chi-
mera and are summarized in Table II.47 Amino acid
conservation at dimer contact sites was determined
by 95% conservation from 25 sequences from geno-
types 1 to 6 from the Los Alamos database.48 Figures
were made using PyMOL (The PyMOL Molecular
Graphics System, Version 1.5.0.4 Schr€odinger, LLC.).
DCV docking and molecular dynamics (MD)
The head-to-head CD-dimer from our structure was
prepared for docking and molecular dynamics (MD)
studies using the Schr€odinger Protein Prep Wizard49
script. This script adds missing amino acid side
chains and optimally adds hydrogen atoms into the
structure. The cleft between the CD-dimer was iden-
tified as a potential binding site and Glide49 from
the Schr€odinger suite of programs was used to ini-
tially dock DCV into this pocket. The resulting
docked structure of DCV was hand-adjusted to
enhance the symmetry of the CD-dimer/DCV com-
plex. The NMR structure of the N-terminal alpha
helices (residues 1–31,39 1R7C.pdb) was grafted onto
each monomer of the CD-dimer/DCV complex. The
missing residues (32–35) were modeled into place
and restraints added to enhance symmetry of the
final modeled structure.
Molecular simulation details
The CD-dimer/DCV complex was placed in a 57.13
3 129.52 3 50.40 A˚3 box with 9917 TIP3P50 water
molecules and eight chloride ions. The MD simula-
tion was carried out with NAMD.51 The
Amber99SB52 force field was used to model the pro-
tein, solvent, and ions, while the General Amber53
force field was used for DCV. The Verlet integration
scheme was used with a multi-time step54 of 2/2/6
and Shake55 was applied to all hydrogen bonds. The
non-bonded interactions were tapered between 8 and
10 A˚ and particle-mesh-Ewald (PME)56 was used for
long range electrostatics. The simulation was run
with periodic boundary conditions in a NPT ensem-
ble at 300 K and 1 atm. The solvated complex was
first subjected to 250 steps of protein backbone-
constrained conjugate gradient minimized followed
by an additional 250 steps of unconstrained conju-
gate gradient minimization. This was followed by
MD heating (10 K increments every 100 steps up to
300 K, NVT ensemble,) and equilibration (250 ps,
NPT ensemble). The MD equilibrated system was
subject to 40 nanoseconds (nsec) of MD and 40,000
frames, one frame per picoseconds (psec), were col-
lected for data analysis.
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